Skip to main content
. 2022 Jul 23;113(9):3169–3179. doi: 10.1111/cas.15474

FIGURE 1.

FIGURE 1

Selection of 219 women with HER2‐positive advanced breast cancer treated with pertuzumab (PER) + trastuzumab (TRA) + chemotherapy (CT) (PTC) or TRA + CT (TC). FAS, full analysis set; IC, informed consent; ITT, intention‐to‐treat; LA/MBC, locally advanced/metastatic breast cancer